Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Sintilimab + S-1 in Unresectable Gastric Cancer
NCT05627414Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jan 2023
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in gastric cancer (GC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: R0 Resection Rate at 1 year. Status: unknown.
02
Drugs
disitamab vedotin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05627414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05627414.